Paper Details

  1. Home
  2. Paper Details

The evolution of dementia in idiopathic Parkinson's disease: neuropsychological and clinical evidence in support of subtypes.

Author: ReidW G

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 107 patients with Parkinson's disease found that the age at which symptoms begin significantly affects the risk and type of cognitive decline. Patients who developed Parkinson's disease at a younger age (under 70) had a lower initial rate of dementia (8%) compared to those who developed the disease later (over 70) (32%). After 3 years of follow-up, dementia prevalence increased to 17% in the younger group and 83% in the older group. This suggests that Parkinson's disease may have two distinct subtypes with different clinical and cognitive features.
Paper Details　
Original Abstract of the Article :
One hundred and seven newly diagnosed, untreated patients with Parkinson's disease (PD) were divided into two groups according to their age at reported onset of symptoms. Of these, 79 patients were under age 70 (early-onset) and 28 patients were age 70 and over (late-onset). The group of 50 control ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1288660

データ提供：米国国立医学図書館（NLM）

Dementia in Parkinson's Disease: A Tale of Two Subtypes

The world of Parkinson's disease is vast and complex, like a desert with many hidden oases. This study delves into a fascinating aspect of this disease: the development of dementia. The researchers utilized a meticulous approach, comparing two groups of Parkinson's disease patients based on their age at symptom onset. They found that there were two distinct subtypes of the disease, each with a unique progression of cognitive decline. The study concluded that age at onset is a crucial factor in predicting the severity and pattern of cognitive impairment in Parkinson's disease.

Age is a Key Determinant of Cognitive Decline in Parkinson's Disease

The research revealed that 8% of the early-onset group and 32% of the late-onset group were classified as demented at baseline. After 3 years, this prevalence increased to 17% in the early-onset group and a whopping 83% in the late-onset group. These striking differences emphasize the critical role age plays in the development of dementia in Parkinson's disease.

Understanding Parkinson's Disease and Dementia

The study's findings can help us better understand the different forms of Parkinson's disease and their impact on cognitive function. This knowledge may lead to more effective treatment strategies tailored to each subtype. As Dr. Camel, I encourage everyone to be aware of the early signs of dementia and seek medical attention promptly. Early diagnosis and treatment can improve the quality of life for individuals with Parkinson's disease and their families.

Dr. Camel's Conclusion

This research, like a desert oasis, provides valuable insights into the complex interplay between Parkinson's disease, age, and dementia. It highlights the importance of personalized care for Parkinson's patients, taking into account individual factors that can affect their cognitive journey. Remember, just as a desert traveler must be prepared for the unexpected, so must we be prepared to understand and navigate the complexities of neurodegenerative diseases.

Date :
  1. Date Completed 1993-03-25
  2. Date Revised 2016-10-20
Further Info :

Pubmed ID

1288660

DOI: Digital Object Identifier

1288660

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.